Skip to main content

Deal Alert: Vyome Biosciences Raises Series A Financing

From the Press Release: 

Vyome Biosciences Private Limited, an innovation driven dermatology company focused on developing novel and innovative treatments for common skin conditions such as dandruff, acne, pigmentation disorders and wound healing, today announced that it has closed Series A financing round of Rs. 18.50 crore. The round was led by IndoUS Venture Partners (IUVP), with Aarin Capital and Navam Capital as coinvestors. 

Vyome will deploy the new financing to advance the clinical development of its lead antidandruff products, and to accelerate the pre-clinical development of its anti-acne products. These safer and more effective next-generation treatments are being developed by harnessing emerging genetic information on the disease-causing microbes with advances in nanotechnology. Vyome has already filed multiple Indian and Global patents on these technologies. “Our vision is to emerge as a company that launches global products from India and competes with the best in the world” said Dr Shiladitya Sengupta, Co-Founder of Vyome and Assistant Professor of Medicine at Harvard Medical School.

“Vyome is developing creative approaches that will transform how skin diseases will be treated in the future. Dermatology is one area that has not seen much innovation for over five decades but with the recent advances in science, significantly more effective solutions become possible. Vyome has attracted top talent globally, and the ability to generate multiple highly differentiated products by harnessing cutting-edge scientific platforms creates a very compelling value proposition” said Dr R.A. Mashelkar, Chairman of Vyome's Board of Directors and former Director General of CSIR.

“We are backing a top notch scientific team assembled in India that is leveraging leadingedge platform technology to develop promising products to address the $20 billion global dermatology market” said Dr Kumar Shiralagi, Managing Director, IUVP. 

“Nanotechnology applications are poised to completely transform the future of pharmacotherapy and consumer products as did biotechnology beginning in the 1980s. We are pleased to support some of the leading academic scientists and ventures in this area” said Dr Ranjan Pai, Managing Partner, Aarin Capital. 

“Navam is delighted to welcome IUVP and Aarin as investors in Vyome. The work Vyome is doing will challenge assumptions and change perceptions about India’s capacity to deliver genuine innovation. We are demonstrating what Indian technology companies can achieve if they focus on building innovative products,” said Rajeev Mantri, Co-Founder and President of Vyome, and Executive Director of Navam Capital. 

About Vyome Biosciences Private Limited 

Vyome is a privately-held biopharmaceutical company based in Delhi focused on the development of novel therapeutics for dermatology applications. The Company, which had raised seed funding from Navam Capital, was founded in August 2010 by Dr Rajesh Gokhale, Director of Institute of Genomics & Integrative Biology in Delhi, Dr Shiladitya Sengupta, Co- Chair at the Center for Regenerative Therapeutics at Brigham & Women’s Hospital in Boston, USA and Assistant Professor of Medicine at Harvard Medical School, and Rajeev Mantri, Executive Director of Navam Capital.

Vyome has assembled a world-class management and scientific team, alongside a Board of Directors and Scientific Advisory Board that collectively have a significant track record of conducting acclaimed scientific research, developing breakthrough products and building sustainable businesses. 

About IUVP 

IndoUS Venture Partners (IUVP) is a leading venture capital firm which provides early and mid- stage funding to new or growing businesses in India. Our team comprises experienced entrepreneurs and executives who understand the model of incubating ideas and transforming them into successful enterprises. It is our privilege to fund entrepreneurial ideas and offer collaborative partnerships. We invest in tomorrow's business leaders, explosive new markets and enterprises that will transform our future. We foster close partnerships with our portfolio companies, and build strong relationships based on integrity, trust and mutual respect. At IUVP, we are committed to redefining Indian entrepreneurship and are excited about India's potential to be an innovative player in the global market. Our approach to investing and our philosophy of building successful companies makes us the ideal partner for entrepreneurs. 

About Navam Capital

Navam Capital is a venture capital firm focused on seed and early-stage investments in energy, life sciences, Internet, advanced materials and other emerging technology sectors. Navam backs innovation-driven companies that are developing significantly differentiated products in the pursuit of large market opportunities. Navam was the founding investor in Vyome Biosciences, investing Rs 4.50 crore in 2010. 

About Aarin Capital 

Aarin Capital invests in innovative ideas in the health care, life sciences and technology based products and services business pursuing large market opportunities that are led by driven and committed teams.

Popular posts from this blog

VC Interview: Shailendra Singh of Sequoia Capital India

In a recent interview to Venture Intelligence, Shailendra Singh discussed some of the firm’s newer investments in the early stage segment including in the online payments space, the progress at a few existing portfolio companies and the active role the firm is playing in helping its portfolio companies scale and succeed in India and globally. Prior to joining the firm in 2006, Singh was a strategy consultant at Bain & Company in New York and before that, an entrepreneur in the digital media industry. Venture Intelligence: How does Sequoia go about identifying potential early stage investments in India? Is there anything different you are doing today than, say, a couple of years back? Shailendra Singh: There is a lot more focus on technology investing and early stage investing. In general, as you might remember a few years ago, we were doing primarily growth investing but in the past 18-odd months, we have had a very strong focus on early stage and that’s continuing. In terms

ChrysCapital, Motilal Oswal PE & Sequoia named PE-VC Firms of the Decade

Press Release ChrysCapital, Motilal Oswal Private Equity and Sequoia Capital India have been named the top Private Equity & Venture Capital investors in India during the last decade, as part of Venture Intelligence’s APEX Awards. The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer.  While ChrysCapital won the “Private Equity Investor of the Decade” award, Motilal Oswal Private Equity was feted as India’s “Growth Capital Investor of the Decade”. The Indian arm of the storied Silicon Valley VC firm, Sequoia Capital, was named the country’s “Venture Capital Investor of the Decade”. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms as well as "crowd sourced" nominations and voting from the Limited Partner, PE-VC and advisory communities. (The main criteria were Exit Track Record, New Fund Raises & Fo

Ambit tops League Table for Transaction Advisors to Private Equity deals in 2019

Ambit Corporate Finance topped the Venture Intelligence League Table for Transaction Advisor to Private Equity Transactions for the year 2019. Ambit advised PE deals worth $2.4 Billion (across 4 qualifying transactions) during the period. Citi ($1.1 Billion across 2 deals) and  Avendus  ($969 million across 12 deals) took the second and third spot. Edelweiss Financial Services ($758 million across 9 deals) and  PwC  ($708 million across 15 deals) completed the top five in 2019.  The  Venture Intelligence League Tables , the first such initiative exclusively tracking transactions involving India-based companies, are based on value of PE and M&A transactions advised by Financial and Legal Advisory firms. Ambit Corporate Finance advised the $1.9 Billion buyout of Pipeline Infrastructure from Reliance Industries   by Brookfield Asset Management  and the IFC and I Squared Capital-backed   Cube Highways' acquisition of Delhi-Agra Toll Road from Reliance Infrastructu

Jio deals help PE investments climb 12% in H1'20 to $18.8 B

Press Release With Reliance Industries' communications unit Jio Platforms attracting 51% of the investment value, Private Equity-Venture Capital (PE-VC) investments in India rose 12% during the first 6 months of 2020 to $18.8 Billion (across 341 deals), shows data from  Venture Intelligence , a research service focused on private company financials, transactions and their valuations. Investments totaling over $9.5 Billion in Jio by a troop of global private equity firms, following social media giant Facebook's $5.7 Billion mid April investment in the company, helped overall PE-VC investments better the $16.8 Billion (across 503 transactions) invested during the same period in 2019. (Note: These figures include Venture Capital investments, but exclude PE investments in Real Estate).   Jio Platforms' $9.5 Billion Private Equity haul (excluding Facebook’s strategic investment) was led by Middle Eastern and American investors with KKR, Saudi Arabia's Public Invest

Inventus, Sixth Sense, Blume & Norwest win Apex'20 Venture Capital Awards

Inventus Capital Partners, Sixth Sense Ventures, Blume Ventures and Norwest Venture Partners were voted the top Venture Capital investors in India during 2019. The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. Other 2019 winners in the VC segment included  Axilor Ventures which was voted   the  Accelerator of the Year for the second year running, 3one4 Capital (VC Fund Raise of the Year) and Innoven Capital (Venture Debt firm of the Year). The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms as well as "crowd sourced" nominations and voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Exit Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies).    " It is an honour to be recognised by entrepreneurs and investors as